scholarly journals Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease

2020 ◽  
Vol 9 (2) ◽  
pp. 594 ◽  
Author(s):  
Silvia Paciotti ◽  
Elisabetta Albi ◽  
Lucilla Parnetti ◽  
Tommaso Beccari

Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease.

2021 ◽  
pp. 107385842199226
Author(s):  
Stellina Y. H. Lee ◽  
Nathanael J. Yates ◽  
Susannah J. Tye

Inflammation is a critical factor contributing to the progressive neurodegenerative process observed in Parkinson’s disease (PD). Microglia, the immune cells of the central nervous system, are activated early in PD pathogenesis and can both trigger and propagate early disease processes via innate and adaptive immune mechanisms such as upregulated immune cells and antibody-mediated inflammation. Downstream cytokines and gene regulators such as microRNA (miRNA) coordinate later disease course and mediate disease progression. Biomarkers signifying the inflammatory and neurodegenerative processes at play within the central nervous system are of increasing interest to clinical teams. To be effective, such biomarkers must achieve the highest sensitivity and specificity for predicting PD risk, confirming diagnosis, or monitoring disease severity. The aim of this review was to summarize the current preclinical and clinical evidence that suggests that inflammatory processes contribute to the initiation and progression of neurodegenerative processes in PD. In this article, we further summarize the data about main inflammatory biomarkers described in PD to date and their potential for regulation as a novel target for disease-modifying pharmacological strategies.


1997 ◽  
Vol 148 (1) ◽  
pp. 135-146 ◽  
Author(s):  
Clive N. Svendsen ◽  
Maeve A. Caldwell ◽  
Jinkun Shen ◽  
Melanie G. ter Borg ◽  
Anne E. Rosser ◽  
...  

Viruses ◽  
2014 ◽  
Vol 6 (8) ◽  
pp. 3293-3310 ◽  
Author(s):  
Travis Lewis ◽  
Joel Glasgow ◽  
Ashley Harms ◽  
David Standaert ◽  
David Curiel

1996 ◽  
Vol 19 (1) ◽  
pp. 69-69
Author(s):  
A. Berardelli ◽  
R. Agostino ◽  
A. Currà ◽  
M. Manfredi

AbstractLatash & Anson's explanation of bradykinesia in patients with Parkinson's disease and cocontraction in dystonic patients is intriguing. However, the proposed adaptive changes in the central nervous system do not fit well with both clinical and experimental evidence of motor impairment in these patients. In particular, we question the explanation of: (1) the role of postural reactions and spatial accuracy in bradykinesia, (2) certain abnormalities during the execution of sequential and simultaneous movements, (3) the sudden changes in mobility (ON and OFF) of Parkinsonian patients, and (4) the meaning of reflex circuitry changes in dystonia.


2015 ◽  
Vol 7 (3) ◽  
Author(s):  
Celmir De Oliveira Vilaça ◽  
Marco Antonio Araujo Leite ◽  
Jano Alves De Souza ◽  
Marco Orsini ◽  
João Santos Pereira ◽  
...  

Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic systems in the central nervous system. In migraine it is supposed to occur hyperactivation of central dopaminergic pathways. We verified the hypothesis of improved migraine in patients who manifest PD. We evaluated 109 patients with PD over 40 years (57 men and 52 women) about the presence throughout the life of migraine, as well as the possibility of improvement in migraine after the onset of motor symptoms of PD. This group was compared to a control group of 152 people (41 men and 152 women) without PD regarding the presence of migraine and its improvement. Twenty-one patients manifested migraine in the group with PD (16 women and 5 men) in which 13 reported improvement in migraine after the onset of symptoms of PD. Among the controls, 37 interviewed had migraine history (32 women and 5 men) among which 20 showed improvement. There was no significant difference when comparing the two groups (χ21:0,05=0.337; P<0.382). We were unable to relate the improvement of migraine with the emergence of PD motor signs, despite the degeneration of dopaminergic pathways of the central nervous system.


2016 ◽  
Vol 2 (1) ◽  
Author(s):  
Laurie K Mischley ◽  
Kevin E Conley ◽  
Eric G Shankland ◽  
Terrance J Kavanagh ◽  
Michael E Rosenfeld ◽  
...  

1997 ◽  
Vol 144 (1) ◽  
pp. 131-138 ◽  
Author(s):  
Philippe Horellou ◽  
Olivier Sabaté ◽  
Marie-Hélène Buc-Caron ◽  
Jacques Mallet

1998 ◽  
Vol 7 (2) ◽  
pp. 109-120 ◽  
Author(s):  
Roy A.E. Bakay ◽  
Kevin L. Boyer ◽  
Curt R. Freed ◽  
Aftab A. Ansari

Allogeneic transplantation for the therapy of human Parkinson's disease is being considered as a viable approach at several clinical centers worldwide. As an attempt to understand the basic biology of central nervous system (CNS) transplantation, our laboratory has developed an experimental nonhuman primate model for human Parkinson's disease and carried out preliminary studies directed at evaluating the potential pathology at the graft site. In addition, studies have been conducted to examine whether such transplantation procedures lead to specific and/or nonspecific immunologic sensitization of the host or results in generalized immunosuppression. Groups of rhesus macaques (Macaca mulatta) were either controls operated (n = 6), autografted with adrenal medullary and peripheral nerve tissue (n = 3), or allografted with fetal mesencephalic tissue (n = 6). Immunohistological studies demonstrated the presence of mononuclear cell infiltrates as early as 1 wk and up to 1 yr postoperatively, although the frequency of the infiltrating cells declined with time. The infiltrates consisted of variable numbers of cells which express CD2+, CD3+, CD4+, CD8+, CD19+, CD22+, CD25+, and CD68+. There appeared to be no difference in the frequency, kinetics, or phenotype of the infiltrating cells in operative controls compared with recipients of auto- or allografts. Tissue sections obtained postoperatively showed low levels of major histocompatibility complex (MHC) Class I antigens and no detectable level of MHC-Class II antigens in neural tissue. A small aliquot of tissue from the operative site was placed in vitro with media containing interleukin-2 (IL-2), which led to the exudation and growth of mononuclear cells that were predominantly CD4+ cells. Phenotypic studies of peripheral blood mononuclear cells (PBMC) from operative controls, auto- and allograft recipient monkeys performed at varying time periods postoperatively failed to show differences in the frequencies of subsets of T-cells, B-cells, NK-cells, or monocytes. Studies on aliquots of the same PBMC failed to show major functional differences in NK-cells, LAK cells, or response to polyclonal mitogens. Finally, recipients of allogeneic mesencephalic grafts failed to show evidence of donor-specific humoral or cellular sensitization. These data indicate that transplantation of autograft adrenal or allograft fetal mesencephalic tissues in the CNS of nonhuman primate did not induce detectable donor-specific sensitization nor nonspecific immunosuppression.


Author(s):  
Vrutangkumar V. Shah ◽  
Sachin Goyal ◽  
Harish Palanthandalam-Madapusi

Parkinson’s disease is an idiopathic and degenerative disorder of the central nervous system. Among the symptoms, the tremor at rest is one of the prominent symptoms. The challenge however is that there are no definitive diagnostic test that can confirm the presence or severity of Parkinson’s disease. This is a serious handicap especially since the drugs usually prescribed to control these symptoms have serious side effects and their dosages have to be tuned extensively. Also, the exact origin of tremor is unknown. There have been recent efforts [19] to understand the mechanism behind the Parkinsonian tremor, from a control-system perspectives. From these efforts, it appears that increased sensorimotor loop delay may be a cause for Parkinsonian tremor and thus serve as a key distinguishing feature. In the current work, we adopted this hypothesis and with the help of a relatively straightforward analysis of the motor control loop along with the help of some simulation and experimental examples, we first attempt to explain several qualitative observations relating to Parkinson’s Disease. Further, we explore the possibilities of for progress tracking, diagnosis, and early diagnosis before onset of tremor using biomechanical means.


Sign in / Sign up

Export Citation Format

Share Document